Voyager Therapeutics, Inc. (NASDAQ: VYGR) is a Healthcare company (Biotechnology) with a market capitalization of $95M. The Maz Rating grades it against the other companies in its sector.
Voyager Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.52, Voyager Therapeutics, Inc. trades at 3.8x sales and 0.7x book value. Over the last twelve months it generated about $25M of revenue and a net loss of $107M. It runs an operating margin of -450.1% and a net margin of -416.3%. It shows return on equity of -63.4%, return on invested capital of -67.8% and a free cash flow yield of -116.1%. On the balance sheet: a debt-to-equity ratio of 0.23 and a current ratio of 6.81. Over the past 52 weeks the share price ranged from $1.50 to $5.48, with a beta of 1.20.
Voyager Therapeutics, Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 17 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Voyager Therapeutics, Inc. (VYGR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 84.5% / 30% · Interest income / Revenue 33.4% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 68.3% / 33% · Receivables / Mkt Cap (36m) 2.73% / 49% · Interest income / Revenue 33.4% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 68.3% / 33.33% · Receivables / Mkt Cap (24m) 2.73% / 33.33% · Interest income / Revenue 33.4% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 66.3% / 33.33% · Receivables / Avg Assets (4Q) 1.28% / 33.33% · Interest income / Revenue 33.4% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 60.3% / 33.33% · (Cash+Recv) / Total Assets 62.7% / 33.33% · Interest income / Revenue 33.4% / 5% | Fail |
No. As of September 2026, Voyager Therapeutics, Inc. (VYGR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Voyager Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 33.4% of each dividend: Voyager Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.